CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,254,314 | -31.5% | 93,728 | -15.3% | 0.02% | -25.9% |
| Q2 2023 | $6,212,452 | -38.6% | 110,660 | -50.6% | 0.03% | -44.9% |
| Q1 2023 | $10,123,198 | -65.5% | 223,816 | -69.0% | 0.05% | -71.2% |
| Q4 2022 | $29,363,324 | -13.1% | 722,345 | +39.7% | 0.17% | +19.7% |
| Q3 2022 | $33,792,000 | -4.3% | 517,100 | -12.3% | 0.14% | +108.8% |
| Q2 2022 | $35,326,452 | -10.0% | 589,746 | -5.7% | 0.07% | -19.0% |
| Q1 2022 | $39,253,000 | +17.2% | 625,332 | +41.5% | 0.08% | +16.7% |
| Q4 2021 | $33,481,000 | -20.6% | 441,818 | +17.3% | 0.07% | -24.2% |
| Q3 2021 | $42,167,000 | -1.3% | 376,725 | +42.7% | 0.10% | -6.9% |
| Q2 2021 | $42,739,000 | +70.6% | 264,000 | +28.4% | 0.10% | +67.2% |
| Q1 2021 | $25,046,000 | +531.5% | 205,544 | +693.6% | 0.06% | +662.5% |
| Q4 2020 | $3,966,000 | +433.1% | 25,900 | +63.9% | 0.01% | +60.0% |
| Q2 2019 | $744,000 | – | 15,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |